Los Angeles Capital Management LLC Decreases Position in Utah Medical Products, Inc. (NASDAQ:UTMD)

Los Angeles Capital Management LLC lowered its position in Utah Medical Products, Inc. (NASDAQ:UTMD) by 8.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,553 shares of the medical instruments supplier’s stock after selling 2,730 shares during the quarter. Los Angeles Capital Management LLC owned 0.88% of Utah Medical Products worth $2,044,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brandes Investment Partners LP increased its holdings in Utah Medical Products by 66.2% during the 2nd quarter. Brandes Investment Partners LP now owns 116,524 shares of the medical instruments supplier’s stock valued at $7,789,000 after acquiring an additional 46,427 shares in the last quarter. Quadrature Capital Ltd increased its stake in shares of Utah Medical Products by 177.6% during the 1st quarter. Quadrature Capital Ltd now owns 32,310 shares of the medical instruments supplier’s stock worth $2,294,000 after purchasing an additional 20,671 shares in the last quarter. Rice Hall James & Associates LLC raised its position in shares of Utah Medical Products by 24.3% during the 3rd quarter. Rice Hall James & Associates LLC now owns 83,338 shares of the medical instruments supplier’s stock worth $5,576,000 after purchasing an additional 16,297 shares during the last quarter. Bank of Montreal Can purchased a new stake in Utah Medical Products in the 2nd quarter valued at approximately $1,039,000. Finally, Vanguard Group Inc. lifted its stake in Utah Medical Products by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 183,141 shares of the medical instruments supplier’s stock valued at $13,023,000 after buying an additional 12,402 shares in the last quarter. Institutional investors and hedge funds own 69.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Utah Medical Products from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th.

Utah Medical Products Trading Down 2.0 %

NASDAQ:UTMD opened at $66.96 on Thursday. Utah Medical Products, Inc. has a 12-month low of $63.38 and a 12-month high of $87.86. The firm has a market cap of $233.02 million, a price-to-earnings ratio of 15.86 and a beta of 0.08. The company’s 50-day moving average is $66.03 and its two-hundred day moving average is $67.34.

Utah Medical Products Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 3rd. Investors of record on Monday, December 16th will be given a dividend of $0.305 per share. The ex-dividend date of this dividend is Monday, December 16th. This represents a $1.22 dividend on an annualized basis and a yield of 1.82%. This is a positive change from Utah Medical Products’s previous quarterly dividend of $0.30. Utah Medical Products’s dividend payout ratio (DPR) is 28.10%.

Utah Medical Products Profile

Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.